Brind.
  1. The Icahn School of Medicine at Mount Sinai is part of the Mount Sinai Health System.

Miriam Merad leads the NYC-Vita clinical trial team as the Icahn School of Medicine at Mount Sinai integrates clinical trials and research enterprise.

2 reports, 2 independent Updated Aug 11
Gone quiet
Reports
2
Developments
4
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Miriam Merad leads the NYC-Vita clinical trial team as the Icahn School of Medicine at Mount Sinai integrates clinical trials and research enterprise.

Who's involved

What this event is mainly about
Mount Sinai Health SystemIcahn School of Medicine at Mount SinaiMiriam Merad

How it developed

Newest first. Tap a step to see who reported it.
  1. Vivek Reddy is named as a lead author and co-principal investigator for a study at Mount Sinai Health System.Sub-event
  2. FDA granted De Novo clearance for VitaSmart™ HOPE System, while Don Webber serves as CEO and President.Sub-event
  3. Miriam Merad leads the NYC-Vita clinical trial team at Mount Sinai.1 source
  4. Mount Sinai discusses WTC effects in Pennsylvania.1 source

Keep exploring

Part of

The Icahn School of Medicine at Mount Sinai is part of the Mount Sinai Health System. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped